Denied and Desperate: The Human Cost of Prior Authorization Rejections and How Patients Can Fight Back

Somewhere between the physician's prescription pad and the pharmacy counter, an invisible gatekeeper sits in judgment. It does not know the patient. It has never reviewed the full medical history. Yet with a single administrative decision, it can determine whether a person receives the medication their doctor prescribed — or spends the next several weeks navigating a bureaucratic maze while their condition worsens.

That gatekeeper is prior authorization, and for millions of Americans, its denials are not merely inconvenient. They are financially and medically catastrophic.

A System Designed for Cost Control, Not Patient Care

Prior authorization — often abbreviated as PA — is a process by which health insurers require physicians to obtain approval before certain medications, procedures, or treatments will be covered under a patient's plan. In theory, the mechanism exists to prevent unnecessary or excessively expensive care. In practice, it frequently functions as a blunt instrument that delays or denies treatments that physicians have already determined to be medically necessary.

According to a 2023 survey conducted by the American Medical Association, 94 percent of physicians reported that prior authorization has at least some negative impact on patient outcomes. More than a third indicated that PA requirements had led to a serious adverse event — including hospitalization — for a patient in their care. These are not edge cases. They are systemic failures embedded in the architecture of American health insurance.

The financial dimension compounds the medical one. When an insurer denies coverage for a prescribed medication, patients face a difficult set of options: pay the full out-of-pocket cost, which for specialty drugs can exceed thousands of dollars per month; wait for an appeal to be processed, which can take weeks; or simply go without.

For patients living paycheck to paycheck, that last option is often the only realistic one.

When the Choice Is Medication or the Mortgage

Consider the experience of patients managing chronic conditions — autoimmune disorders, severe depression, Type 2 diabetes, or rheumatoid arthritis — who depend on medications that insurers frequently flag for prior authorization review. These are not elective treatments. They are the chemical scaffolding that allows people to function.

A 47-year-old teacher in Ohio managing lupus described waiting nearly three weeks after her insurer denied authorization for a biologic her rheumatologist had prescribed. During that period, she rationed her previous medication, skipped doses, and watched her symptoms escalate. "I was calling the insurance company every other day," she said. "Meanwhile, I couldn't walk to my car without pain."

A 31-year-old single father in Georgia, prescribed an antidepressant after a psychiatric hospitalization, received a denial notice four days after his discharge. His psychiatrist had selected the medication based on his specific history and prior treatment failures. The insurer's preferred alternative had already proven ineffective. Faced with a $340 monthly cost to fill the prescription out of pocket, he chose to pay his electric bill instead.

These are not outliers. They are the predictable outcomes of a system that prioritizes cost containment over clinical judgment.

The Appeals Process Most Patients Never Use

What many patients do not realize — in part because insurers are not always forthcoming about it — is that a prior authorization denial is not a final verdict. Federal law and most state regulations guarantee patients the right to appeal an adverse coverage decision, and in many cases, those appeals succeed.

There are generally two stages to the appeals process: an internal appeal, handled by the insurer, and an external review, conducted by an independent third party. For urgent medical situations, insurers are typically required to process expedited appeals within 72 hours. Standard appeals must be resolved within 30 to 60 days, depending on the state and the type of plan.

Physicians play a critical role in the appeals process. A well-documented letter of medical necessity — one that explains why the prescribed medication is appropriate for the specific patient and why alternatives are inadequate — significantly improves the likelihood of a successful appeal. Patients should request this documentation from their prescriber as soon as a denial is received.

Additionally, many states have enacted legislation establishing independent external review processes that are binding on insurers. Patients who are denied after an internal appeal have the right to request this external review, and statistics from several states suggest that patients win a meaningful percentage of external reviews — sometimes more than half.

Despite these protections, the process demands time, persistence, and health literacy that many patients simply cannot afford. The burden falls disproportionately on those who are already managing serious illness.

Navigating the Gap: What Happens While You Wait

The period between a denial and a resolution is often the most dangerous interval for patients. Conditions can deteriorate. Hospitalizations can occur. And the stress of financial uncertainty compounds the physical toll of untreated illness.

During this window, several resources may be available. Pharmaceutical manufacturers frequently offer patient assistance programs for high-cost medications, providing free or reduced-cost access while insurance disputes are resolved. Physicians can sometimes prescribe a formulary-approved alternative — though, as in the Georgia case above, a substitute is not always clinically equivalent.

This is where the efficiency of home delivery pharmacy services can make a meaningful difference. When an appeal results in approval — or when a prescriber and patient agree to pivot to an alternative medication that does not require prior authorization — the speed of fulfillment matters enormously. A patient who has already lost weeks to the appeals process should not then spend additional days waiting for a pharmacy to process a new prescription.

Services like MedDelivered are structured to move quickly once authorization is in place. Prescriptions can be transferred or submitted electronically, insurance information is verified at the point of order, and medications are dispatched directly to the patient's home. For individuals who have been managing a coverage dispute while also dealing with symptoms, transportation barriers, or work obligations, that reduction in friction is not a minor convenience — it is a meaningful intervention.

A Call for Systemic Reform

Home delivery services can ease the logistical burden of navigating a denied authorization, but they cannot fix the underlying problem. The prior authorization system, as currently structured, imposes measurable harm on patients — and reform efforts at both the federal and state level are ongoing.

The Improving Seniors' Timely Access to Care Act, which passed the House of Representatives with bipartisan support, would impose new transparency and timeliness requirements on Medicare Advantage plans. Several states have enacted gold-carding laws that exempt physicians with strong approval track records from routine PA requirements. These are incremental steps, but they represent growing recognition that the status quo is untenable.

In the meantime, patients facing denials should document everything, pursue appeals aggressively, engage their prescribing physicians as active advocates, and explore all available assistance programs. And when the authorization finally comes through, they should not have to wait another week at a pharmacy counter.

That part, at least, can be made easier.